Global Diabetic Neuropathy Market Projected to Expand at 10.2% CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Diabetic Neuropathy Market Expected To Become By 2029 Compared With Its 2025 Level?

The market size for diabetic neuropathy has experienced significant growth in recent years. It is forecast to expand from $5.79 billion in 2024 to $6.21 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be credited to factors such as increasing global diabetes prevalence, improved awareness and diagnosis, developments in diabetic care, rising healthcare expenditure, investments in research and development, and patient education initiatives.

The diabetic neuropathy market is anticipated to undergo swift expansion in the coming years, with projections indicating it will reach $9.15 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 10.2%. This growth over the forecast period is attributed to advancements in neuroimaging, patient-centric care approaches, the expansion of clinical trials, the persistent increase in diabetes cases, precision medicine approaches, the broader application of regenerative medicine, and patient advocacy and support programs. Significant trends expected during this period include collaborative endeavors in medical research, digital health solutions, progress in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, and the integration of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp

Which Industry Drivers Are Expected To Accelerate The Diabetic Neuropathy Market From 2025 To 2029?

The increasing occurrence of diabetes is anticipated to propel the expansion of the diabetic neuropathy market moving forward. Diabetes is a chronic condition where the body struggles to effectively utilize and store glucose, a type of sugar. This disorder manifests when the body either fails to produce an adequate amount of insulin, a hormone critical for regulating blood sugar, or does not use insulin efficiently. Diabetic neuropathy is a form of nerve damage that can affect individuals with diabetes, leading to various types of nerve impairment and distinct symptoms. For instance, in August 2022, the IDF Diabetes Atlas report, published by the International Diabetes Federation—a global diabetes community based in Belgium and an umbrella organization representing over 230 national diabetes associations—stated that 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. Currently, 537 million adults (aged 20–79) are living with diabetes, accounting for 1 in 10 people. This figure is projected to climb to 643 million by 2030 and 783 million by 2045. Therefore, the growing prevalence of diabetes is a significant driver for the growth of the diabetic neuropathy market.

Which Key Segments Fueling The Diabetic Neuropathy Market?

The diabetic neuropathymarket covered in this report is segmented –

1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy

2) By Drug Class: Analgesics; Anti-Depressants; Anti-Convulsants; Other Drug Classes

3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments

4) By Distribution Channel: Online Distribution; Offline Distribution

5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:

1) By Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyneuropathy

2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy; Gastrointestinal Autonomic Neuropathy; Genitourinary Autonomic Neuropathy

3) By Proximal Neuropathy: Diabetic Amyotrophy; Lumbosacral Plexus Neuropathy

4) By Focal Neuropathy: Cranial Neuropathy; Cervical Radiculopathy; Other Focal Neuropathies

Which Trends Are Impacting The Diabetic Neuropathy Market?

Leading companies in the diabetic neuropathy market are developing advanced products, such as neuromodulation therapy devices, to improve treatment options for individuals experiencing chronic pain linked to diabetic neuropathy. These neuromodulation therapy devices offer non-invasive treatment by modulating nerve activity to alleviate pain, enhance nerve function, and promote healing in patients with diabetic nerve damage. For instance, in January 2024, Neuralace Medical, Inc., a US-based company specializing in non-drug pain management, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency, for its Axon Therapy for Chronic Painful Diabetic Neuropathy. The Axon Therapy device is specifically designed to treat chronic painful diabetic neuropathy (CPDN). This innovative therapy utilizes neuromodulation techniques to provide relief from pain associated with diabetic neuropathy, signifying a major advance in pain management choices for patients with this condition. The clearance highlights the device’s safety and effectiveness, enabling Neuralace to proceed with commercialization and broaden access to effective treatment solutions for those affected by CPDN.

Which Key Players Are Driving Competition In The Diabetic Neuropathy Market?

Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

What Are The Regional Market Dynamics Impacting The Diabetic Neuropathy Industry?

North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Diabetic Neuropathy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9057&type=smp

Browse Through More Reports Similar to the Global Diabetic Neuropathy Market 2025, By The Business Research Company

Neurology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Neurodegenerative Disorder Therapeutic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795